ISRG Intuitive Surgical Inc.

Intuitive Launches $100 Million Venture Capital Fund

Intuitive Launches $100 Million Venture Capital Fund

Intuitive Ventures to accelerate the future of minimally invasive care

SUNNYVALE, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the launch of Intuitive Ventures. The inaugural $100 million fund will invest in the future leaders of minimally invasive care.

Intuitive Ventures is focused on investment opportunities in digital tools, precision diagnostics, focal therapeutics and platform technologies that share Intuitive’s commitment to advancing positive outcomes in healthcare. The fund will support independent initiatives in the direct and adjacent fields of minimally invasive care and marks the entrance into the venture capital space for parent company Intuitive.

“The future of minimally invasive care spans the patient journey from early diagnosis to treatment and beyond,” said Julian Nikolchev, President of Intuitive Ventures. ”Intuitive Ventures is investing in cutting-edge innovation across the continuum of care to bring the future forward.”

Nikolchev brings a deep entrepreneurial and operational background with more than 30 years of experience in the development and commercialization of therapeutic medical devices, including leading early stage teams and technologies through growth and market transformation. He joined Intuitive Surgical in 2019 and will continue to serve as its Senior Vice President of Corporate Development and Strategy.

Nikolchev is joined by Intuitive Ventures Director Dr. Oliver Keown MD, who joined Intuitive in 2019 to co-found the fund. Keown was previously an investor at GE Ventures where he drove international deal-flow and supported digital and MedTech portfolio companies operationally and at the board level. He also advised U.K., U.S. and global healthcare innovation projects across commercial, government, and academic fields.

“We are value-add investors who leverage access to Intuitive’s unique industry expertise and customer connections,” Keown said. “Our nimble structure and alignment with the startups we will back empower us to invest early and support our portfolio companies as they pioneer markets.’’

About Intuitive Ventures

Leveraging Intuitive’s entrepreneurial spirit and expansive technological and clinical reach, Intuitive Ventures invests in transformative opportunities advancing positive outcomes in healthcare. The fund is focused on U.S. and international early stage start-ups and takes a long-term outlook to support portfolio companies reach their major milestones. Through its inaugural $100 million fund and with leadership combining decades of investing and operational experience, the team cultivates strategic resources to drive financial returns and accelerate the future of minimally invasive care. Intuitive Ventures has already started deploying capital and is actively building its portfolio. More information and future updates can be found at: ventures.intuitive.com

About Intuitive

Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, Calif., is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. As part of our mission, we believe that minimally invasive care is life-enhancing care. Through ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints.

Intuitive brings more than two decades of leadership in robotic-assisted surgical technology and solutions to its offerings, and develops, manufactures and markets the da Vinci® surgical system and the Ion™ endoluminal system.

For more information, please visit the company’s website at .

Forward-Looking Statements

This press release contains forward-looking statements about Intuitive Ventures and its plans to invest in early-stage companies, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; uncertainties regarding the ability of Intuitive Ventures to identify investment candidates; uncertainties regarding the success of Intuitive Ventures’ investments; uncertainties and variables inherent in the operating and financial performance in investments made, including, among other things, competitive developments and general economic, political, business, industry, regulatory and market conditions; future exchange and interest rates; and changes in tax and other laws, regulations, rates and policies. The Company undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

Contact

Global Public Affairs

Intuitive Surgical



Source: Intuitive Surgical, Inc.

EN
27/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intuitive Surgical Inc.

 PRESS RELEASE

Da Vinci 5 Cleared for Cardiac Procedures

Da Vinci 5 Cleared for Cardiac Procedures FDA 510(k) clearance expands da Vinci 5 indications to include certain cardiac procedures SUNNYVALE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the da Vinci 5 system for certain cardiac procedures, including mitral valve repair and IMA (internal mammary artery) mobilization for cardiac revascularization.         Cardiovascular disease remains the l...

 PRESS RELEASE

20 Million Patients Benefit from da Vinci Surgery Globally

20 Million Patients Benefit from da Vinci Surgery Globally Achievement reflects the dedication of surgeons and care teams worldwide to improving patient outcomes through use of Intuitive’s minimally invasive technologies SUNNYVALE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced that more than 20 million patients worldwide have been operated on by surgeons using da Vinci surgical systems. The milestone was reached as of the end of 2025, with more than 3.1 mil...

 PRESS RELEASE

Intuitive Announces Fourth Quarter Earnings

Intuitive Announces Fourth Quarter Earnings SUNNYVALE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2025. Q4 Highlights Worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately 17% and Ion procedures grew approximately 44%.The Company placed 532 da Vinci surgical systems, compared with...

 PRESS RELEASE

Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Resu...

Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results SUNNYVALE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Financial and Operational Highlights Fourth quarter 2025 worldwide procedures (da Vinci and Ion combined) grew approximately 18...

 PRESS RELEASE

Intuitive Announces Expanded Indications for da Vinci SP

Intuitive Announces Expanded Indications for da Vinci SP FDA clearance expands da Vinci SP indications to include inguinal hernia repair, cholecystectomy, and appendectomy SUNNYVALE, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the da Vinci Single Port (SP) surgical system for use in inguinal hernia repair, cholecystectomy, and appendectomy procedures. These clearances expand da Vinci SP’s ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch